Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Cancer Research UK: Clinical Trials & FDA Approval Profile

Cancer Research UK (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (12 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.5%
Median Closed Enrollment vs National (145 pts)34 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Cancer Research UK
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)13 (12)
Completed vs Stopped Early1 / 2 (12.5%)
Median Closed Actual Enrollment34 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Cancer Research UK
Hospital Research SiteLocationShared Protocols
Churchill HospitalOxford10
Addenbrooke's HospitalCambridge, Cambridgeshire9
Southampton General HospitalSouthampton9

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Cancer Research UK
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07440290DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAFPhase II/IIIRECRUITING
NCT05786716DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With CancPhase II/IIIRECRUITING
NCT05770544DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.Phase II/IIIRECRUITING
NCT05770102DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour MutationaPhase II/IIIRECRUITING
NCT05770037DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersPhase II/IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Cancer Research UK Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI